Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: Cancer Immunol Immunother. 2013 May 18;62(8):1347–1357. doi: 10.1007/s00262-013-1437-3

TLR8 stimulation directly matures DC and additively enhances cetuximab-mediated DC maturation. (A) DC were incubated with TLR8 selective agonist VTX-2337 (800nM) or with media for 48 h. TLR8 stimulation increased DC expression of %CD80 (p<0.001), %CD83 (p<0.05), and CD86 median FI (p<0.005). (B) DC were co-cultured with NK cells and PCI-15B HNC cells at 1:1:1 ratio. Cetuximab treatment alone enhanced DC maturation: %CD80 (p<0.01), %CD83 (p<0.001) and CD86 median FI (p<0.05), as previously observed. TLR8 stimulation alone modestly enhanced DC maturation: %CD80 (p<0.01), %CD83 (p<0.01). Addition of TLR8 stimulation to cetuximab treatment additively enhances DC maturation: %CD80 (p<0.01), %CD83 (0<0.001). Cetuximab was used at 10μg/mL. *p<0.05, **p<0.01, ***p<0.005 (C225:Cetuximab VTX:VTX-2337)

TLR8 stimulation directly matures DC and additively enhances cetuximab-mediated DC maturation. (A) DC were incubated with TLR8 selective agonist VTX-2337 (800nM) or with media for 48 h. TLR8 stimulation increased DC expression of %CD80 (p<0.001), %CD83 (p<0.05), and CD86 median FI (p<0.005). (B) DC were co-cultured with NK cells and PCI-15B HNC cells at 1:1:1 ratio. Cetuximab treatment alone enhanced DC maturation: %CD80 (p<0.01), %CD83 (p<0.001) and CD86 median FI (p<0.05), as previously observed. TLR8 stimulation alone modestly enhanced DC maturation: %CD80 (p<0.01), %CD83 (p<0.01). Addition of TLR8 stimulation to cetuximab treatment additively enhances DC maturation: %CD80 (p<0.01), %CD83 (0<0.001). Cetuximab was used at 10μg/mL. *p<0.05, **p<0.01, ***p<0.005 (C225:Cetuximab VTX:VTX-2337)